KBC Group’s Insys Therapeutics, Inc. INSY Stock Holding History

KBC Group’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-52,606	Closed	-$16K	–	1527
2019 Q2	$16K	Buy	+52,606	New	+$142K	﹤0.01%	1426
2015 Q4	–	Sell	-23,434	Closed	-$667K	–	1352
2015 Q3	$667K	Sell	23,434 -12,858	-35%	-$473K	0.01%	699
2015 Q2	$1.3M	Sell	36,292 -5,908	-14%	-$184K	0.02%	669
2015 Q1	$1.23M	Buy	+42,200	New	+$1.12M	0.02%	681
2014 Q3	–	Sell	-144,566	Closed	-$2.26M	–	1352
2014 Q2	$2.26M	Buy	+144,566	New	+$2.34M	0.03%	568

KBC Group's INSY Position: Q3 2019 in Review

KBC Group sold out of Insys Therapeutics, Inc. (INSY) in Q3 2019, closing a stake of 52,606 shares — an estimated $16K sold.

KBC Group first reported a position in INSY in Q2 2014 and held it in 5 quarters. The position peaked at $2.26M in Q2 2014. 4 funds tracked by Wall St. Rank hold INSY as of Q3 2019.

KBC Group reported no remaining Insys Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
KBC Group sold 52,606 Insys Therapeutics, Inc. shares in Q3 2019, an estimated $16K.
KBC Group first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
KBC Group's Insys Therapeutics, Inc. position peaked at $2.26M in Q2 2014.
4 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2019.

Based on KBC Group's 13F filing for Q3 2019, filed 7 Nov 2019.